Clinical Trials Browser

Uterine Neoplasms × dostarlimab × 90 days × Clear all

NCT05559879 2026-04-15

Cabozantinib and Dostarlimab in Recurrent Gynecologic Carcinosarcoma

Phase 1/2 Recruiting

Carcinoma, Uterine Neoplasms, Endometrial Neoplasms